Priovant Publishes Phase 3 Brepocitinib Skin Outcomes

Regulatory and clinical development teams tracking first-in-class TYK2/JAK1 inhibitor programs should note that Priovant Therapeutics has published skin-specific secondary endpoint data from the Phase 3 VALOR trial in JAMA Dermatology, adding a substantive cutaneous evidence package to primary results already on record in the New England Journal of Medicine.

The VALOR trial evaluated brepocitinib 30 mg, an oral dual TYK2 and JAK1 inhibitor, against placebo in adults with dermatomyositis. Across the skin-specific analyses, treatment effects were detectable at Week 4 and sustained through Week 52. In patients with at least moderate itch at baseline, 54% of brepocitinib-treated patients achieved clinically meaningful itch reduction by Week 4, compared with 10% on placebo; by Week 52, those figures reached 74% versus 33%, respectively.

Remission-level outcomes at Week 52 are particularly relevant for benefit-risk documentation in a future submission. Among patients with moderate-to-severe skin disease at baseline, 45.7% of brepocitinib 30 mg patients achieved a two-category improvement on the Investigators Global Assessment to "Clear" or "Almost Clear," versus 21.8% on placebo. Functional skin remission on the CDASI-A score was reached by 43.5% of brepocitinib patients compared with 20.8% on placebo. Statistically significant improvement in CDASI-A response at Week 52 was also recorded, with 61.7% of brepocitinib patients versus 44.3% on placebo achieving a clinically meaningful threshold (delta 16.8%; 95% CI 1.1-32.5; P=0.04).

For regulatory affairs leads, the dual-journal publication strategy is notable. Separating primary efficacy and safety data from organ-specific secondary endpoints across two high-impact publications creates a structured evidentiary record that maps closely to the multi-domain endpoint architecture regulators expect in submissions for systemic autoimmune conditions. The cutaneous data, covering disease activity, itch, and skin-related quality of life, directly addresses the patient-reported outcome requirements that FDA guidance increasingly emphasises in chronic inflammatory disease programs.

Manufacturing and CMC teams planning for potential NDA or BLA submission timelines should factor in that brepocitinib is an oral small molecule, placing process validation and commercial-scale production planning within a conventional solid oral dosage framework, though the TYK2/JAK1 selectivity profile will require close attention to impurity characterisation and stability data packages consistent with ICH Q10 and applicable 21 CFR Part 211 requirements.

The completeness of the VALOR skin dataset, now spanning two peer-reviewed publications, positions the brepocitinib program for a regulatory submission package in which cutaneous endpoints carry independent evidentiary weight alongside the previously reported muscle and functional outcomes.

Source: Priovant Therapeutics via GlobeNewswire, 26 August 2026.